Power3 Medical Receives Additional Blood Samples to Continue Testing for Early Protein Indicators of Breast Cancer

THE WOODLANDS, Texas, Dec. 15, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces that the Company has received additional blood samples from Mercy Women's Center in Oklahoma City, Oklahoma to continue testing to identify and track protein biomarkers for the early indication of breast cancer in blood serum. This marks the second large batch of samples to be tested as part of a recent research agreement between Power3 Medical and Mercy Women's Center.

During the past year, Mercy and Breast MRI of Oklahoma have been collecting blood samples from women undergoing MRI of the breast. This database now accounts for the largest collection of samples tied to MRI results in the country. Power3 believes that the larger the number of blood samples tested, the more accurate their team can become in identifying specific protein biomarkers that are unique to women with breast cancer.

According to Dr. Ira Goldknopf, Power3 Medical Chief Scientific Officer, "We are delighted to continue our collaboration with Mercy, as a major component of our discovery process is obtaining clinically relevant patient samples. I am encouraged by our initial discoveries utilizing blood serum to detect critical proteins associated with this devastating disease. We continue to believe that the key to detection of breast cancer at its earliest stages lies in the changes of one's proteins."

About Power3 Medical Products Inc.

Power3 Medical is a leading edge biotechnology company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases that the Company's proprietary technology can detect in patients. These discoveries are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. The Company operates a state-of-the-art proteomics laboratory in The Woodlands, Texas.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.


Contact Data